clinical trial · NCT05165485
Phase 4 COPD and Suboptimal Inspiratory Flow Rate
Theravance Biopharma·phase4·completed·n = 404
Chronic Obstructive Pulmonary DiseaseRevefenacinTiotropiumRevefenacin PlaceboTiotropium Placebo
brief summary
Study is a randomized, double-blind, double-dummy, parallel-group study evaluating efficacy and safety of revefenacin vs. tiotropium in adults with severe to very severe COPD and suboptimal PIFR.
started
Jan 7, 2022
primary completion
Nov 13, 2023
completion
Nov 20, 2023
last updated
Dec 20, 2024
official title
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered Via Standard Jet Nebulizer or Tiotropium Delivered Via a Dry Powder Inhaler (Spiriva® HandiHaler®)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol